DSM increases price for polyamide 6 and 66 in EMEA
The price increases are due to the rising costs of raw materials.
The price increases are due to the rising costs of raw materials.
Jubilant announced the completion of demerger of pharma and LSI business into two separate companies
WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).
Novasep's viral vector business is an excellent strategic fit as Thermo Fisher continues to expand its capabilities for cell and gene vaccines and therapies globally," said Michel Lagarde, executive vice president, Thermo Fisher.
Subscribe To Our Newsletter & Stay Updated